AACR: AstraZeneca offers first look at Imfinzi's resectable lung cancer showing, fueling a key debate

AstraZeneca has offered the first look at the benefit of a PD-1/L1 inhibitor when used both before and after surgery in resectable non-small cell lung cancer. But the data raise more questions than answers.